- Home
- MVST vs CMRX Comparison
MVST vs CMRX Comparison
Compare MVST & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- CMRX
- Stock Information
- Founded
- MVST 2006
- CMRX 2000
- Country
- MVST United States
- CMRX United States
- Employees
- MVST N/A
- CMRX N/A
- Industry
- MVST Industrial Machinery/Components
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- CMRX Health Care
- Exchange
- MVST Nasdaq
- CMRX Nasdaq
- Market Cap
- MVST 676.9M
- CMRX 797.3M
- IPO Year
- MVST N/A
- CMRX 2013
- Fundamental
- Price
- MVST $1.83
- CMRX $8.54
- Analyst Decision
- MVST Strong Buy
- CMRX Hold
- Analyst Count
- MVST 1
- CMRX 4
- Target Price
- MVST $3.00
- CMRX $8.51
- AVG Volume (30 Days)
- MVST 8.7M
- CMRX 2.0M
- Earning Date
- MVST 05-08-2025
- CMRX 04-30-2025
- Dividend Yield
- MVST N/A
- CMRX N/A
- EPS Growth
- MVST N/A
- CMRX N/A
- EPS
- MVST N/A
- CMRX N/A
- Revenue
- MVST $379,801,000.00
- CMRX $212,000.00
- Revenue This Year
- MVST $24.47
- CMRX $2,416.04
- Revenue Next Year
- MVST $25.25
- CMRX $923.92
- P/E Ratio
- MVST N/A
- CMRX N/A
- Revenue Growth
- MVST 23.87
- CMRX N/A
- 52 Week Low
- MVST $0.15
- CMRX $0.75
- 52 Week High
- MVST $2.87
- CMRX $8.55
- Technical
- Relative Strength Index (RSI)
- MVST 59.50
- CMRX 80.86
- Support Level
- MVST $1.61
- CMRX $8.50
- Resistance Level
- MVST $1.80
- CMRX $8.55
- Average True Range (ATR)
- MVST 0.23
- CMRX 0.02
- MACD
- MVST 0.03
- CMRX -0.12
- Stochastic Oscillator
- MVST 91.36
- CMRX 88.89
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.